Andrew A Young

Summary

Affiliation: Amylin Pharmaceuticals
Country: USA

Publications

  1. ncbi request reprint Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
    A A Young
    Amylin Pharmaceuticals, San Diego, California 92121, USA
    Diabetes 48:1026-34. 1999
  2. ncbi request reprint Dose-response for inhibition by amylin of cholecystokinin-stimulated secretion of amylase and lipase in rats
    Andrew A Young
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Regul Pept 130:19-26. 2005
  3. ncbi request reprint Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, Suite 110, San Diego, California 92121, USA
    Endocrinology 146:2069-76. 2005
  4. doi request reprint Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Dr, Ste 110, San Diego, CA 92121, United States
    Int J Pharm 356:231-8. 2008
  5. ncbi request reprint Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
    Loretta L Nielsen
    Amylin Pharmaceuticals Inc, 9360 Town Centre Dr Ste 110, San Diego, CA 92121, USA
    Regul Pept 117:77-88. 2004
  6. ncbi request reprint Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187
    Bronislava R Gedulin
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Regul Pept 137:121-7. 2006
  7. ncbi request reprint Obesity: a peptide YY-deficient, but not peptide YY- resistant, state
    Andrew A Young
    Amylin Pharmaceuticals Inc, San Diego, California 92121, USA
    Endocrinology 147:1-2. 2006
  8. pmc A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice
    Desu Chen
    National Center for Drug Screening, 189 Guo Shou Jing Road, Zhangjiang High Tech Park, Pudong, Shanghai 201203, China
    Proc Natl Acad Sci U S A 104:943-8. 2007

Collaborators

Detail Information

Publications8

  1. ncbi request reprint Glucose-lowering and insulin-sensitizing actions of exendin-4: studies in obese diabetic (ob/ob, db/db) mice, diabetic fatty Zucker rats, and diabetic rhesus monkeys (Macaca mulatta)
    A A Young
    Amylin Pharmaceuticals, San Diego, California 92121, USA
    Diabetes 48:1026-34. 1999
    ..0 microg/kg+/-0.15 log and 2.4 microg/kg+/-0.41 log, respectively. In conclusion, acute and chronic administration of exendin-4 has demonstrated an antidiabetic effect in several animal models of type 2 diabetes...
  2. ncbi request reprint Dose-response for inhibition by amylin of cholecystokinin-stimulated secretion of amylase and lipase in rats
    Andrew A Young
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Regul Pept 130:19-26. 2005
    ..The neuroendocrine hormone amylin, cosecreted with insulin from pancreatic beta-cells in response to nutrient ingestion, has several physiologic actions to limit the rate of nutrient uptake, including the slowing of gastric emptying...
  3. ncbi request reprint Exenatide (exendin-4) improves insulin sensitivity and {beta}-cell mass in insulin-resistant obese fa/fa Zucker rats independent of glycemia and body weight
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc, 9360 Towne Centre Drive, Suite 110, San Diego, California 92121, USA
    Endocrinology 146:2069-76. 2005
    ....
  4. doi request reprint Pharmacokinetics and pharmacodynamics of exenatide following alternate routes of administration
    Bronislava R Gedulin
    Amylin Pharmaceuticals, Inc 9360 Towne Centre Dr, Ste 110, San Diego, CA 92121, United States
    Int J Pharm 356:231-8. 2008
    ..Despite little optimization of the delivery formulation, exenatide bioavailability compared favorable to that of several commercially available bioactive peptides...
  5. ncbi request reprint Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes
    Loretta L Nielsen
    Amylin Pharmaceuticals Inc, 9360 Town Centre Dr Ste 110, San Diego, CA 92121, USA
    Regul Pept 117:77-88. 2004
    ....
  6. ncbi request reprint Role of endogenous amylin in glucagon secretion and gastric emptying in rats demonstrated with the selective antagonist, AC187
    Bronislava R Gedulin
    Amylin Pharmaceuticals Inc, 9360 Towne Centre Drive, San Diego, CA 92121, USA
    Regul Pept 137:121-7. 2006
    ..These data collectively indicate a physiologic role for amylin in glucose homeostasis via mechanisms that include regulation of glucagon secretion and gastric emptying...
  7. ncbi request reprint Obesity: a peptide YY-deficient, but not peptide YY- resistant, state
    Andrew A Young
    Amylin Pharmaceuticals Inc, San Diego, California 92121, USA
    Endocrinology 147:1-2. 2006
  8. pmc A nonpeptidic agonist of glucagon-like peptide 1 receptors with efficacy in diabetic db/db mice
    Desu Chen
    National Center for Drug Screening, 189 Guo Shou Jing Road, Zhangjiang High Tech Park, Pudong, Shanghai 201203, China
    Proc Natl Acad Sci U S A 104:943-8. 2007
    ..Thus, Boc5 behaved as a full GLP-1 mimetic in vitro and in vivo. The chemical genus represented by Boc5 may prompt the exploration of orally available GLP-1R agonists with potential utility in diabetes and obesity...